Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Vaxart COVID-19 vaccine

From Wikipedia, the free encyclopedia
Vaccine candidate against COVID-19

Pharmaceutical compound
Vaxart COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Other namesVXA-CoV2-1, VXA-CoV2-1.1-S, VXA-CoV2-3.1
Routes of
administration
Oral
Identifiers
CAS Number
Part ofa series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
virus iconCOVID-19 portal

Vaxart COVID-19 vaccine is aCOVID-19 vaccine candidate developed byVaxart.[2][3][4] It is anenteric-coated tablet vaccine that can be administered orally.[5]

References

[edit]
  1. ^"Patent Landscape Report COVID-19-related vaccines and therapeutics"(PDF).
  2. ^Clinical trial numberNCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" atClinicalTrials.gov
  3. ^Clinical trial numberNCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" atClinicalTrials.gov
  4. ^Clinical trial numberNCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" atClinicalTrials.gov
  5. ^Braun MR, Flitter BA, Sun W, Tucker SN (October 2023). "An easy pill to swallow: oral recombinant vaccines for the 21st century".Current Opinion in Immunology.84 102374.doi:10.1016/j.coi.2023.102374.PMID 37562075.
logo
Development
Classes
Administration
Vaccines
Bacterial
Viral
Protozoan
Helminthiasis
Other
Inventors/
researchers
Controversy
Related
Pre-pandemic
2020
2021
2022
2023
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
By location
Others
Data (templates)
Global
Africa
Americas
Asia
Europe
Oceania
Others
Portals:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vaxart_COVID-19_vaccine&oldid=1314558104"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp